Other
Postprandial Distress Syndrome
0
Pipeline Programs↗
2
Active Trials↗
2
Companies Involved↗
Postprandial Distress Syndrome is an early-stage landscape with 0 programs across 2 companies. The most active players are Getz Pharma, Tasly Pharmaceutical Group Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Not yet recruiting1 · 25%
Terminated1 · 25%
Recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
Terminated·—·Phase 2·NCT00630370·6 enrolled
Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)
Unknown status·XXiyuan Hospital of China Academy of Chinese Medical Sciences·Phase 1/2·NCT02762136·216 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)